Ticker
ADAP

Price
2.22
Stock movement up
+- (%)
Company name
Adaptimmune Therapeutics Plc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Markedsverdi
359.68M
Ent verdi
526.80M
Pris/omsetning
38.72
Pris/bok
2.20
Utbytte avkastning
-
Utbytte vekst
-
Vekst år
-
FCF-utbetaling
-
Etterfølgende P/E
-
Fremtidig P/E
-
PEG
-
EPS-vekst
-
1 års avkastning
-55.15%
3 års avkastning
15.79%
5 års avkastning
-15.78%
10 års avkastning
-
Sist oppdatert: 2022-08-25

UTBYTTE

ADAP betaler ikke utbytte

VERDSETTELSE

Verdsettelsesforhold

Loading...
Verdsettelsesforhold-data
Etterfølgende P/E-
Pris til OCF125.41
Pris til FCF-
Pris til EBITDA-
EV i forhold til EBITDA-

Verdsettelse (Salg/Bokført verdi)

Loading...
Verdsettelse (Salg/Bokført verdi) data
Pris til omsetning38.72
Pris til bok2.20
EV i forhold til salg56.71

ØKONOMI

Per aksje

Loading...
Per aksje-data
Gjeldende aksje antall162.02M
EPS (TTM)-1.09
FCF per aksje (TTM)-0.07

Resultatregnskap

Loading...
Resultatregnskap-data
Inntekter (TTM)9.29M
Bruttofortjeneste (TTM)9.29M
Driftsinntekter (TTM)-124.36M
Netto inntekt (TTM)-170.17M
EPS (TTM)-1.09
EPS (1 år fremover)-0.83

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)100.00%
Driftsmargin (TTM)-1338.61%
Fortjenestemargin (TTM)-1831.79%

Balanse

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Balanse-data
Kontanter89.54M
Netto fordringer42.89M
Samlede omløpsmidler359.46M
Goodwill0.00
Immaterielle eiendeler788.00K
Eiendom, anlegg og utstyr0.00
Sum eiendeler419.80M
Leverandørgjeld7.02M
Kortsiktig/nåværende langsiktig gjeld25.95M
Sum kortsiktig gjeld66.15M
Sum gjeld256.65M
Aksjonærenes egenkapital163.15M
Netto varige driftsmidler162.36M

Kontantstrøm

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Kontantstrøm-data
Kontantstrøm fra drift (TTM)2.87M
Kapitalutgifter (TTM)14.58M
Fri kontantstrøm (TTM)-11.72M
Utbetalt utbytte (TTM)0.00

Finansielle inntekter

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Finansielle inntekter-data
Egenkapitalavkastning-104.31%
Avkastning på eiendeler-40.54%
Avkastning på investert kapital-102.59%
Kontantavkastning på investert kapital-7.06%

AKSJEINFORMASJON

Aksjediagram

Loading...
Aksjekurs-data
Åpning2.27
Daglig høy2.33
Daglig lav2.17
Daglig volum154K
Tidenes høyeste21.12
1 år analytikerestimat5.67
Beta1.84
EPS (TTM)-1.09
Utbytte per aksje-
Ex-div dato-
Neste dato for resultatpresentasjon-

Nedsidepotensial

Loading...
Nedsidepotensial-data
ADAPS&P500
Nåværende prisfall fra toppnotering-89.49%-12.18%
Høyeste prisfall-96.57%-56.47%
Dato for høyeste fall15 Nov 20199 Mar 2009
Gj.snittlig fall fra topp-69.23%-11.38%
Gj.snittlig tid til ny topp368 days12 days
Maks tid til ny topp1813 days1805 days
SELSKAPSOPPLYSNINGER
ADAP (Adaptimmune Therapeutics Plc) company logo
Markedsverdi
359.68M
Markedsverdi kategori
Small-cap
Beskrivelse
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing aß T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Ansatte
494
Investorrelasjoner
-
SEC-innsendelser
Adm. direktør
Adrian Rawcliffe
Land
USA
By
Abingdon
Aksjetype
American depositary share
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRESENTASJONER
ArrangementerPresentasjoner
Loading...
FORSTÅ VIRKSOMHETEN
Loading...
NYHETER OM SELSKAPET
Alle nyheterPressemeldinger
Adaptimmune Therapeutics plc (NASDAQ: ADAP) announces data from its signal-finding Phase 1 SURPASS trial of ADP-A2M4CD8 in solid tumor settings. The data will be presented at the European Society for ...
9. september 2022
- 44% Objective Response Rate (ORR) with a single dose of ADP-A2M4CD8 in 25 heavily pre-treated patients with late-stage ovarian, urothelial, and head & neck cancers -- Further clinical development pl...
9. september 2022
- Event to be held on Friday, September 9th, at 8 a.m. EDT -Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 25, 2022) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a l...
25. august 2022
Today is shaping up negative for Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) shareholders, with the analysts...
10. august 2022
- Reaffirming financial guidance; Company funded into early 2024 -- ASCO data confirms afami-cel potential for synovial sarcoma; BLA submission on-track for Q4 2022 - - Update from signal-finding Phas...
4. august 2022
Adaptimmune Therapeutics plc ( NASDAQ:ADAP ) shareholders should be happy to see the share price up 12% in the last...
1. august 2022
Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - July 21, 2022) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report financ...
21. juli 2022
Here's why these Fool.com contributors are bullish on Adaptimmune Therapeutics, G1 Therapeutics, and Axsome Therapeutics.
1. juli 2022
If you want to know who really controls Adaptimmune Therapeutics plc ( NASDAQ:ADAP ), then you'll have to look at the...
1. juli 2022
Shares of the British cell therapy company Adaptimmune Therapeutics (NASDAQ: ADAP) are having one of their best days in several months today. To put this move into the proper context, the bellwether ...
27. juni 2022
Neste side